These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19227607)

  • 21. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
    Bonnick SL; Silverman S; Tanner SB; Martens M; Bachmann G; Kohles JD; Civitelli R
    J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis.
    Lewiecki EM
    J Clin Densitom; 2008; 11(4):478-84. PubMed ID: 18757222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to manage postmenopausal osteoporosis?
    Body JJ
    Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.
    Sambrook P
    Clin Interv Aging; 2007; 2(1):65-72. PubMed ID: 18044076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ibandronate once a month].
    Polk B
    Med Monatsschr Pharm; 2006 Jan; 29(1):36-7. PubMed ID: 16463553
    [No Abstract]   [Full Text] [Related]  

  • 27. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quarterly intravenous ibandronate for postmenopausal osteoporosis.
    Emkey RD
    Womens Health (Lond); 2008 May; 4(3):219-28. PubMed ID: 19072470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD
    Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.
    Miller PD; Ward P; Pfister T; Leigh C; Body JJ
    Clin Exp Rheumatol; 2008; 26(6):1125-33. PubMed ID: 19210886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.
    Zaidi M; Epstein S; Harris ST; Kohles JD; Chesnut CH
    Ann N Y Acad Sci; 2007 Nov; 1117():273-82. PubMed ID: 18056047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
    Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
    Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on osteoporosis management in long-term care: focus on bisphosphonates.
    Kamel HK
    J Am Med Dir Assoc; 2007 Sep; 8(7):434-40. PubMed ID: 17845945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT; Safi W; Trinh H
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ibandronate (boniva) offers new options for osteoporosis.
    Kessenich CR
    Nurse Pract; 2006 Oct; 31(10):64-6. PubMed ID: 17028500
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.